Molbreevi, Savara's sole molecule in development for treatment of aPAP, hit a nasty speed bump when the FDA issued its RTF. Savara is working to get the program back on track so that it can file a new ...

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic ...

(RTTNews) - Savara Inc. (SVRA), a biopharmaceutical company, Thursday announced that it has introduced the aPAP ClearPath Dried Blood Spot Test in the U.S. This new test builds on its prior ...